Eli Lilly executed a coordinated Phase 3 site expansion across its full eloralintide and orforglipron complication-specific program today, while two Novo Nordisk early-pipeline molecules (NNC0113-5840, NNC0497-0040) both opened recruitment in Phase 1. — 4 trials with material updates.
← All Projects |

Competitive Intelligence · Obesity and Type 2 Diabetes

Thursday, June 4, 2026

Eli Lilly executed a coordinated Phase 3 site expansion across its full eloralintide and orforglipron complication-specific program today, while two Novo Nordisk early-pipeline molecules (NNC0113-5840, NNC0497-0040) both opened recruitment in Phase 1.

Key Signals · 4 trials updated

  • NCT07566390 — Novo Nordisk NNC0113-5840 (tracked amylin-pathway molecule), Phase 1 obesity: NOT_YET_RECRUITING → RECRUITING confirmed at v1 (2026-06-01); n=48, PCD 2026-11-26.
  • NCT07578584 — Novo Nordisk NNC0497-0040 (tracked molecule, obesity/T1D), Phase 1: NOT_YET_RECRUITING → RECRUITING confirmed at v1 (2026-06-01); n=146, PCD 2028-02-18.
  • Eli Lilly eloralintide (LY3841136) Phase 3 program — 5 indication-specific trials (T2D obesity, non-T2D obesity, OSA, OA, incretin-persistent obesity) all added sites simultaneously today: NCT07282600, NCT07321886, NCT07353931, NCT07369011, NCT07392190.
  • Eli Lilly orforglipron + retatrutide Phase 3 program — 5 trials (OA, urinary incontinence, CV outcomes, PAD, retatrutide obesity) added sites simultaneously today: NCT07153471, NCT07202884, NCT07223593, NCT07241390, NCT07357415.
  • NCT07627074 — Novo Nordisk semaglutide real-world observational study (n=35,000) first posted 2026-05-30; noted for scale, not promoted as a clinical trial signal.

Scan parameters

  • Window: 2026-06-04 (1-day floor; most recent prior painswick report was 2026-06-04)
  • Passes: (a) conditionQuery obesity/overweight/T2DM, Phase 2/3; (b) tracked molecules × priority sponsors, no condition/phase filter; (c) priority sponsors × same conditions, phases EARLY_PHASE1/PHASE1/PHASE4/NA
  • Pass (a): 22 hits; pass (b): 16 hits; pass (c): 2 hits. Deduped unique: ~26. In-scope candidates: ~20 after filtering non-tracked sponsors.

1. NCT07566390 — NNC0113-5840 Phase 1 | RECRUITMENT OPENED

NCT07566390 · Novo Nordisk · Phase 1 · n=48 · RECRUITING

Signal: Status transition — NOT_YET_RECRUITING → RECRUITING.

Version evidence: v1 (2026-06-01) changed OverallStatus to RECRUITING; prior v0 (2026-04-29) was NOT_YET_RECRUITING. Modules: Study Status, Contacts/Locations. Transition confirmed within window.

Context: NNC0113-5840 is an explicitly tracked Novo Nordisk molecule in the obesity pipeline. A Phase 1 study in overweight/obese participants (n=48, PCD 2026-11-26) opening recruitment is an early clinical readiness signal. The short PCD (~6 months) suggests a single-ascending-dose or first-in-human design. This is the first clinical recruitment milestone for this molecule.

2. NCT07578584 — NNC0497-0040 Phase 1 | RECRUITMENT OPENED

NCT07578584 · Novo Nordisk · Phase 1 · n=146 · RECRUITING

Signal: Status transition — NOT_YET_RECRUITING → RECRUITING.

Version evidence: v1 (2026-06-01) changed OverallStatus to RECRUITING; prior v0 (2026-05-05) was NOT_YET_RECRUITING. Modules: Study Status, Contacts/Locations. Transition confirmed within window.

Context: NNC0497-0040 is an explicitly tracked Novo Nordisk molecule, studied here in healthy participants, overweight/obese adults, and T1D patients with overweight/obesity (n=146, PCD 2028-02-18). The larger sample and T1D arm suggest a broader Phase 1 pharmacology program than NNC0113-5840. Two tracked-molecule Phase 1 programs opening recruitment within the same week (both v1 dated 2026-06-01) indicates a coordinated pipeline push from Novo Nordisk's early-stage obesity portfolio.

3. Eli Lilly eloralintide Phase 3 program — Coordinated site expansion

Signal: Simultaneous Contacts/Locations updates across five indication-specific Phase 3 trials on 2026-06-04.

Trials (all Eli Lilly, all RECRUITING):

  • NCT07282600 — eloralintide in obesity + T2D; Phase 3; n=1,035; PCD 2028-01
  • NCT07321886 — eloralintide in obesity without T2D; Phase 3; n=1,980; PCD 2028-03
  • NCT07353931 — eloralintide in OA knee + obesity; Phase 3; n=900; PCD 2028-03
  • NCT07369011 — eloralintide in OSA + obesity; Phase 3; n=800; PCD 2028-03
  • NCT07392190 — eloralintide in persistent obesity on incretin; Phase 3; n=900; PCD 2028-06

Version evidence (representative — NCT07357415 retatrutide): v12 (2026-06-03) touched Study Status + Contacts/Locations; prior v11 (2026-05-20) same modules. Status unchanged RECRUITING. Site additions pattern confirmed.

Context: Eloralintide (LY3841136) is Lilly's amylin analog. Simultaneously expanding all five indication-specific trials in a single day — covering obesity+T2D, obesity alone, OA, OSA, and incretin-failure obesity — signals aggressive global enrollment coordination. Combined enrollment target across these five trials exceeds 5,600 participants. The coordinated expansion is consistent with Lilly accelerating toward 2028 readouts across its amylin program. Geographies: all trials are global programs; site additions are in scope under global geography filter.

4. Eli Lilly orforglipron + retatrutide Phase 3 program — Coordinated site expansion

Signal: Simultaneous Contacts/Locations updates across five additional Phase 3 trials on 2026-06-04.

Trials (all Eli Lilly, all RECRUITING):

  • NCT07153471 — orforglipron in OA knee + obesity; Phase 3; n=800; PCD 2028-04
  • NCT07202884 — orforglipron in stress urinary incontinence + obesity; Phase 3; n=1,000; PCD 2028-03
  • NCT07223593 — orforglipron in peripheral artery disease; Phase 3; n=1,205; PCD 2028-06
  • NCT07241390 — orforglipron ATTAIN-Outcomes (CV/CKD); Phase 3; n=7,140; PCD 2031-08
  • NCT07357415 — retatrutide in obesity without T2D; Phase 3; n=600; PCD 2028-10

Context: Lilly's oral GLP-1 (orforglipron) is expanding into complication-specific indications at scale — OA, urinary incontinence, PAD, and the 7,140-patient cardiovascular outcomes trial (ATTAIN-Outcomes) are all adding sites simultaneously. The combined enrollment target for this cluster exceeds 10,745. The single-day coordination across 10 total Phase 3 trials (eloralintide + orforglipron/retatrutide combined) represents one of the largest coordinated site-expansion events observed in this therapy area.

Materiality gate — Not promoted

  • NCT06584916 (ATTAIN-MAINTAIN, orforglipron, COMPLETED): v7 (2026-06-02) modules were Study Status + Study Description + Conditions + Eligibility + IPDSharing — purely administrative. Status was already COMPLETED at v6 (2025-12-18), predating the window. NOISE.
  • NCT07627074 (Novo Nordisk semaglutide real-world, n=35,000): Observational study first posted 2026-05-30. Not a clinical trial. Noted for scale — may signal Novo Nordisk building a large real-world evidence base for semaglutide label maintenance.
  • Academic and non-tracked-sponsor trials (UNC tirzepatide/endometrial, Hansoh HS-20094, Hengrui SHR-3167, NIDDK alpha-lipoic acid): outside scope.

Generated by Claude Code + ClinicalTrials.gov MCP · clinicaltrials.gov
Rendered: 2026-06-05T02:12:47.120Z · prompt 42e9576168ed · scope 4be2410a4a6d